How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,198 results for

Multiple Endocrine Neoplasia Type 1

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors Full Text available with Trip Pro

across various endocrine tumor types, possibly indicating a deeper pathophysiological mechanism behind endocrine cancer genesis and development. For example, carbohydrate antigen (CA) is measured in both pancreatic adenocarcinoma as well as ovarian cancer for diagnosis, surveillance, and risk stratification. The discovery of measuring miRNAs that are highly expressed in malignant tumors is also a novel strategy across multiple endocrine tumor types, and is propelling the future advancement (...) Current Standards and Recent Advances in Biomarkers of Major Endocrine Tumors The complexity of endocrine tumor diagnosis stems from its variable symptoms and presentation that may mimic many other disease states, or display asymptomatic properties for a prolonged amount of time. Early and accurate disease identification is needed for better patient prognosis. The key to this may be in using validated biomarkers with enhanced sensitivity and specificity. Several biomarkers are consistently used

2018 Frontiers in pharmacology

142. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total <sup>68</sup>Ga-DOTATATE-Avid tumor volume measurements. Full Text available with Trip Pro

peptide (VIP) and pancreatic polypeptide (PP), and 24-h urinary 5-hydroxyindoleacetic acid (5-HIAA) levels were measured. Correlation between biomarkers and total 68Ga-DOTATATE-avid tumor volume (TV) was analyzed.The analysis included 232 patients. In patients with pancreatic NETs (n = 112), 68Ga-DOTATATE TV correlated with CgA (r = 0.6, P = 0.001, Spearman). In patients with multiple endocrine neoplasia type 1 (n = 39), 68Ga-DOTATATE TV correlated with glucagon (r = 0.5, P = 0.01) and PP levels (r (...) Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-Avid tumor volume measurements. To determine the association between neuroendocrine tumor (NET) biomarker levels and the extent of disease as assessed by 68Ga DOTATATE PET/CT imaging.A retrospective analysis of a prospective database of patients with NETs.Fasting plasma chromogranin A (CgA), neuron-specific enolase (NSE), gastrin, glucagon, vasoactive intestinal

2017 European Journal of Endocrinology

143. Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1 Full Text available with Trip Pro

Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1 Pancreatico-duodenal tumors are the second most common endocrinopathy in multiple endocrine neoplasia syndrome type 1, and have a pronounced effect on life expectancy as the principal cause of disease-related death. Previous discussions about surgical management have focused mainly on syndromes of hormone excess and, in particular, the management of multiple endocrine neoplasia syndrome type 1 (...) together with enucleation of tumors in the head of the pancreas, and in cases with Zollinger-Ellison syndrome, excision of duodenal gastrinomas together with clearance of regional lymph node metastases. This strategy, with early and aggressive surgery before metastases have developed, is believed to reduce the risks for tumor recurrence and malignant progression.

2012 Clinics

144. Proliferation Rates of Multiple Endocrine Neoplasia Type 1 (MEN1)-Associated Tumors. Full Text available with Trip Pro

Proliferation Rates of Multiple Endocrine Neoplasia Type 1 (MEN1)-Associated Tumors. Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the combined occurrence of parathyroid and adrenocortical tumors, and neuroendocrine tumors (NETs) of the pancreas and pituitary. The pancreatic NETs are predominantly gastrinomas and insulinomas, and the pituitary NETs are mostly prolactinomas and somatotrophinomas. We postulated that the different types of pancreatic (...) and pituitary NETs may be partly due to differences in their proliferation rates, and we therefore assessed these in MEN1-associated tumors and gonadal tumors that developed in mice deleted for an Men1 allele (Men1(+/-)). To label proliferating cells in vivo, Men1(+/-) and wild-type (Men1(+/+)) mice were given 5-bromo-2-deoxyuridine (BrdU) in drinking water from 1-12 wk, and tissue sections were immunostained using anti-BrdU and hormone-specific antibodies. Proliferation in the tumors of Men1(+/-) mice

2012 Endocrinology

145. Adenocarcinoma of the pancreas

The diagnosis of pancreas cancer may be preceded by non-specific symptoms (e.g.: fatigue, anorexia, weight loss, dull epigatric pain). Early satiety, malabsorption, steatorrhea, glucose intolerance, and jaundice (from extra-hepatic biliary obstruction) may also occur. Risk factors include age, male gender, chronic pancreatitis, diabetes mellitus type 2, germline mutations in P 16 and BRCA2, and a familial predisposition (e.g.: multiple endocrine neoplasia type 1, hereditary non- polyposis colon cancer (...) the age of 18 years with pancreatic cancer. Different principles may apply to pediatric patients. RECOMMENDATIONS AND DISCUSSION Suggested Diagnostic Work-Up A CT scan of the chest and abdomen with or without an MRI of the abdomen (and other tests, as clinically indicated) distinguish between resectable and unresectable disease. CLINICAL PRACTICE GUIDELINE GI-006 Version 9 Page 5 of 11 Stage Information Table 1. AJCC Cancer Staging System for Adenocarcinoma of the Pancreas and Ampulla, Seventh Edition

2015 CPG Infobase

146. Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor Full Text available with Trip Pro

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor Adrenocortical carcinoma (ACC) during childhood is a rare malignant tumor that frequently results in glucocorticoid and/or androgen excess. When there are signs of microscopic or macroscopic residual disease, adjuvant therapy is recommended with mitotane, an adrenolytic and cytotoxic drug. In addition to the anticipated side effect of adrenal insufficiency, mitotane is known to cause gynecomastia (...) and hypothyroidism in adults. It has never been reported to cause precocious puberty. A 4-year-old girl presented with a 6-week history of virilization and elevated androgen levels and 1-year advancement in bone age. Imaging revealed a right adrenal mass, which was subsequently surgically excised. Histology revealed ACC with multiple unfavorable features, including high mitotic index, capsular invasion and atypical mitoses. Adjuvant chemotherapy was started with mitotane, cisplatin, etoposide and doxorubicin

2018 Endocrinology, diabetes & metabolism case reports

147. A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Malignancies Condition or disease Intervention/treatment Phase Cancer of Pancreas Cancer of Liver Cancer of Rectum Cancer of Colon Cancer, Gall Bladder Myeloma Multiple Glioblastoma Multiforme Drug: Cannabidiol Drug: Bortezomib Drug: Leucovorin Drug: 5-FU Drug: Oxaliplatin Drug: Bevacizumab Drug: Irinotecan Drug: Gemcitabine Drug: Temozolomide Phase 1 Phase 2 Detailed Description: Several studies have shown a potential anti-tumor role for cannabinoids by modulating cell signaling pathways, inhibiting (...) Colonic Neoplasms Rectal Neoplasms Gallbladder Neoplasms Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Digestive System

2018 Clinical Trials

148. A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)

closely with the FDG-PET scan. The rationale for using high doses of this radiopharmaceutical agent for treatement is that most malignant lesions have accentuated glucose metabolism, which is mirrored by increased uptake of FDG. Since FDG cannot be metabolized within the cell like glucose, it is effectively confined within the cancer cells; thus, FDG treatment is potentially a novel form of targeted therapy for tumors with increased FDG uptake. Condition or disease Intervention/treatment Phase (...) Radiosensitive Stage IV Solid and Hematological Tumors With High FDG Uptake Not Responding to Standard of Care Lung Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Pancreatic Cancer, Colon Cancer, Lymphomas, Sarcomas, Etc Radiation: FDG Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 6 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title

2014 Clinical Trials

149. Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

– extent: “considerable” ? 1 AE – hint of greater harm – extent: “major” a: Specific AEs include outcomes from different outcome categories. For a detailed presentation, see Table 34 in Appendix B of the full dossier assessment. AE: adverse event; FACT-G: Functional Assessment of Cancer Therapy-General; FKSI-DRS: Functional Assessment of Cancer Therapy – Kidney Symptom Index – Disease-Related Symptoms; SAE: serious adverse event On the positive side, there was an indication of considerable added (...) dossier assessment. AE: adverse event; CI: confidence interval; CSZ: convexity, symmetry, z score; CTCAE: Common Terminology Criteria for Adverse Events; FACT-G: Functional Assessment of Cancer Therapy-General; FKSI-DRS: Functional Assessment of Cancer Therapy – Kidney Symptom Index – Disease-Related Symptoms; HR: hazard ratio; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; IVRS: interactive voice response system; n: number of patients with (at least one) event; N: number

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

150. Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

therapy AE adverse event AJCC American Joint Committee on Cancer CI confidence interval CTCAE Common Terminology Criteria for Adverse Events G-BA Gemeinsamer Bundesausschuss (Federal Joint Committee) EMA European Medicines Agency EQ-5D European Quality of Life-5 Dimensions FACT-G Functional Assessment of Cancer Therapy-General FKSI-DRS Functional Assessment of Cancer Therapy – Kidney Symptom Index – Disease-Related Symptoms IMDC International Metastatic Renal Cell Carcinoma Database Consortium IQWiG (...) for using the RR. e: No usable data available; for reasons, see Section 2.7.4.3 of the full dossier assessment. AE: adverse event; CI: confidence interval; CSZ: convexity, symmetry, z score; CTCAE: Common Terminology Criteria for Adverse Events; FACT-G: Functional Assessment of Cancer Therapy-General; FKSI-DRS: Functional Assessment of Cancer Therapy – Kidney Symptom Index – Disease-Related Symptoms; HR: hazard ratio; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; IVRS

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

151. Recurrent hyperparathyroidism due to proliferation of autotransplanted parathyroid tissue in a multiple endocrine neoplasia type 2A patient Full Text available with Trip Pro

Recurrent hyperparathyroidism due to proliferation of autotransplanted parathyroid tissue in a multiple endocrine neoplasia type 2A patient About 20%-30% of all cases of multiple endocrine neoplasia type 2A (MEN 2A) is accompanied by primary hyperparathyroidism. These patients undergo parathyroidectomy and, if needed, autotransplantation. In rare cases, autotransplanted parathyroid tissues can cause hypoparathyroidism due to failure of transplantation or hyperparathyroidism due to proliferation (...) of the transplanted tissue. A 68-year-old female with MEN 2A underwent left adrenalectomy for pheochromocytoma 15 years prior to presentation and total thyroidectomy, central and right lateral neck lymph node dissection, and subtotal parathyroidectomy with autotransplantation for medullary thyroid cancer and primary hyperparathyroidism 6 years previous. Recently, a doubtful parathyroid adenoma was detected in the left sternocleidomastoid muscle on ultrasonography and on an additional sestamibi scan. The mass

2016 Annals of surgical treatment and research

152. Perioperative Severe Hypotension in a Patient with Multiple Endocrine Neoplasia Type IIb and Bilateral Adrenalectomies: Time to Review the Evidence for Stress Dose Steroids Full Text available with Trip Pro

Perioperative Severe Hypotension in a Patient with Multiple Endocrine Neoplasia Type IIb and Bilateral Adrenalectomies: Time to Review the Evidence for Stress Dose Steroids Multiple endocrine neoplasia type IIb (MEN IIb) is an endocrine disorder which can manifest with tumors such as pheochromocytomas and neuromas. We present the case of a patient with MEN IIb, after bilateral adrenalectomies, on maintenance steroid replacement, who underwent a neuroma resection and developed severe hypotension

2016 Case reports in anesthesiology

153. Local recurrence of pheochromocytoma in multiple endocrine neoplasia type 2A: a diagnostic and therapeutic challenge Full Text available with Trip Pro

Local recurrence of pheochromocytoma in multiple endocrine neoplasia type 2A: a diagnostic and therapeutic challenge In a patient with multiple endocrine neoplasia type 2A (MEN2A), an inverted physiological ratio between urinary normetanephrines and metanephrines is an early marker of recurrence in epinephrine-secreting pheochromocytoma, and 131I MIBG treatment appears to be a useful therapeutic option in order to avoid multiple invasive surgical procedures in pheochromocytomatosis.

2016 Clinical Case Reports

154. Positive Germline Selection in Pedigrees With Multiple Endocrine Neoplasia Type 2 Carrying V804M Mutation in the RET Gene Full Text available with Trip Pro

Positive Germline Selection in Pedigrees With Multiple Endocrine Neoplasia Type 2 Carrying V804M Mutation in the RET Gene Multiple endocrine neoplasia (MEN) type 2 is an autosomal dominant cancer syndrome associated with the development of thyroid cancer and tumors or hyperplasia in other endocrine organs. It is caused by mutations in the RET gene and can be phenotypically classified into MEN types 2A and 2B. MEN2B is often sporadic resulting from a spontaneous mutation, M981T. A positive

2016 World journal of oncology

155. Genetic analysis and clinical investigation of a pedigree with multiple endocrine neoplasia type 2A: A case report Full Text available with Trip Pro

Genetic analysis and clinical investigation of a pedigree with multiple endocrine neoplasia type 2A: A case report Multiple endocrine neoplasia 2A (MEN2A) is characterized by the coexistence of tumors that involve two or more endocrine glands within the same patient, and is defined as the occurrence of medullary thyroid carcinoma in association with pheochromocytoma (PHEO) and parathyroid tumors or hyperparathyroidism. The pathogenesis of MEN2A is due to the mutation of a tyrosine kinase

2016 Oncology letters

156. Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Full Text available with Trip Pro

Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma. Medullary thyroid carcinoma (MTC) is a manifestation of multiple endocrine neoplasia type 2 (MEN2) syndromes caused by germline, activating mutations in the RET (REarranged during Transfection) proto-oncogene. Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC.We conducted a phase I/II trial

2013 Clinical Cancer Research Controlled trial quality: uncertain

157. Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update. Full Text available with Trip Pro

Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update. Over the last decade, our knowledge of the multiple endocrine neoplasia (MEN) type 2 syndromes MEN2A and MEN2B and familial medullary thyroid carcinoma (FMTC) has expanded greatly. In this manuscript, we summarize how recent discoveries have enhanced our understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients.We reviewed the English (...) literature through PubMed from 2000 to the present, using the search terms medullary thyroid carcinoma, multiple endocrine neoplasia type 2, familial medullary thyroid carcinoma, RET proto-oncogene, and calcitonin.Over 70 RET mutations are known to cause MEN2A, MEN2B, or FMTC, and recent findings from studies of large kindreds with these syndromes have clouded the relationship between genotype and phenotype, primarily because of the varied clinical presentation of different families with the same RET

2013 Journal of Clinical Endocrinology and Metabolism

158. Hidden diagnosis of multiple endocrine neoplasia-1 unraveled during workup of virilization caused by adrenocortical carcinoma Full Text available with Trip Pro

Hidden diagnosis of multiple endocrine neoplasia-1 unraveled during workup of virilization caused by adrenocortical carcinoma Multiple endocrine neoplasia-1 (MEN1) is an autosomal dominant syndrome with classic triad of parathyroid hyperplasia, pancreatic neuroendocrine tumors, and pituitary adenomas. Other recognized manifestations include carcinoid, cutaneous or adrenocortical tumors. It is commonly presented with clinical features related to parathyroid, pancreas or pituitary lesions. Here (...) , we have presented a case that had virilization and biochemical Cushing's syndrome due to adrenocortical carcinoma as presenting feature of MEN1. Cushing's syndrome in MEN1 is an extremely rare and usually late manifestation and most cases are due to corticotropin-producing pituitary adenomas. Although Cushing's syndrome generally develops years after the more typical manifestations of MEN1 appear, it may be the primary manifestation of MEN1 syndrome particularly when related to adrenal adenoma

2013 Indian journal of endocrinology and metabolism

159. Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

cancer metastatic lung cancer KIF5B-RET CCDC6-RET NCOA4-RET advance solid tumor Additional relevant MeSH terms: Layout table for MeSH terms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Thyroid Diseases Thyroid Neoplasms Thyroid Cancer, Papillary Carcinoma, Neuroendocrine Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Endocrine System Diseases Endocrine Gland Neoplasms Head and Neck (...) for their disease. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 360 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Actual Study Start Date : March 17, 2017 Estimated Primary Completion Date

2017 Clinical Trials

160. Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion

in and Exported from the U.S.: No Keywords provided by Scottish Clinical Trials Research Unit: Neoadjuvant Venous Tumour Thrombus Axitinib Mayo Classification Nephrectomy Thrombectomy Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Renal Cell Thrombosis Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Embolism and Thrombosis (...) of enrolment. The presence of active second malignancy. Patients will be eligible if they have adequately treated basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer, stable prostate cancer or if treated with curative intent for any other cancer with no evidence of disease for 2 years. Patients with prostate cancer will be permitted entry if not receiving treatment and prostrate-specific antigen (PSA) is not rising. Women who are pregnant or are breastfeeding. Female patients must

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>